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cancer metastasis model
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Diane R. Bielenberg1,2 & Bruce R. Zetter1,2
1Vascular Biology Program, Boston Children’s Hospital, Karp Family Research Laboratories, 300 Longwood Ave., Boston, MA
02115, 2Department of Surgery, Harvard Medical School, Boston, MA 02115, 3Cytoskeleton and Cell Plasticity lab, Life Sciences
Research Unit-FSCT, University of Luxembourg, L-1511 Luxembourg, Luxembourg.
Using an in vivo cycling strategy, we selected metastatic cancer cells from the lymph nodes (LN) of mice
bearing orthotopic DU145 human prostate tumors. Repeated rounds of metastatic selection (LN1–LN4)
progressively increased the epithelial phenotype, resulting in a new model of tumor cell
mesenchymal-epithelial transition (MET). DU145-LN4 showed increased cell-cell adhesions, higher
expression of multiple epithelial markers, such as E-cadherin, EpCAM and cytokeratin 18, and reduced
expression of mesenchymal markers such as vimentin. The MET in DU145-LN4 cells was accompanied by
increased expression of themiR-200 family, and antimiRs tomiR-200c andmiR-141 induced an EMT.MET
also correlated with the loss of miR-424. Ectopic transient and stable miR-424 expression induced EMT,
with reduced epithelial marker expression and increased cell scattering. Our model provides evidence for
spontaneous MET in vivo. We show that this cellular plasticity can be mediated through the combined
action of miR-424 and the miR-200 family.
M
etastases are responsible for most cancer deaths1. Metastasis is a complex, multistep process that still
remains poorly understood. Cells must first escape from the primary tumor mass, invade surrounding
extracellularmatrix, intravasate into lymphatic and blood vessels and establish secondary tumors. Initial
steps in this process are aided by the phenotype and gene expression changes that occur during epithelial-
mesenchymal transition (EMT). During tumor cell EMT, cell-cell junctions are lost and cells become more
motile, secrete proteases and re-express many markers in the embryonic EMT differentiation program2. These
characteristics promote invasion and dissociation. However, there is controversy surrounding the role of EMT in
metastasis in vivo3–6. Pathology studies indicate that metastases usually show a similar heterogeneous epithelial
architecture to the primary tumor7, despite suggestions that stem-like disseminating tumor cells are responsible
for metastasis formation during early stages of primary cancer growth8. As metastases display a dominantly
epithelial phenotype, it would follow that tumor cells show plasticity, undergoing the reverse process, a mesench-
ymal to epithelial transition (MET) in order to grow and successfully establish a nodule at the metastatic site9.
Despite a massive literature supporting the role of EMT in cancer, there has been limited evidence for MET.
Several key studies provided evidence for an MET in vivo10–12, and two recent studies have provided convincing
evidence of the requirement forMET inmetastasis formation. Tsai et al. showed that a Twist-induced EMTmust
be reversed in order for squamous cell carcinoma metastases to form13, and Ocan˜a et al. showed that suppression
of the EMT-inducing homeobox factor, Prrx1, was required for the formation of breast cancer metastases14.
Cellular plasticity may be influenced by many factors including other tumor cells, cells in the microenviron-
ment, or extracellular matrix15. MicroRNAs (miRNAs) have also been established as key regulators of EMT16,17,
and many down-regulate well established EMT-associated transcription factors, such as ZEB1, ZEB2, TWIST,
Oct-4 and SNAI1. The relative importance of various miRNA species in tumor plasticity and the crosstalk
between them is not yet understood.
Prostate cancer is the second leading cause of cancer-related death for men in the US, with most of the
estimated 28,000 yearly deaths resulting frommetastases18. Predictive models in prostate cancer show that lymph
node metastasis results in a poorer prognosis for patients, compared to patients without lymph node involve-
ment19,20. Tumor cell escape via lymphatic vessels to the sentinel lymph node may represent a stepping stone for
more widespread metastasis via the vascular system to distant organs, such as bone21. Understanding the
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mechanisms of lymph node metastasis could facilitate the develop-
ment of new biomarkers and therapeutic options. This may be espe-
cially important in prostate cancer as more patients opt for a
‘watchful waiting’ or active surveillance strategy to manage organ-
confined disease22.
In this report we have used an orthotopic mousemodel of prostate
cancer metastasis, and have repeatedly selected spontaneous meta-
stases from the sentinel lymph nodes. Human cancer cell xenografts
in the orthotopic site are provided relevant environmental signals
compared to an ectopic (often subcutaneous) site, resulting in
enhanced tumorigenicity23. The microenvironment is well estab-
lished to influence tumor cell behavior, capable of stimulating or
repressing cell plasticity, proliferation, migration and invasion24–26.
The selection of highlymetastatic variants from regional lymph node
metastasis following orthotopic prostate xenografts has been
reported using PC-3 and LNCaP prostate cancer cells23,27. These cells
have proven highly valuable to the prostate cancer research com-
munity. In this report we describe a new model developed using the
DU145 human prostate cancer cell line. DU145 is a widely used
‘‘classical’’ prostate cancer cell line that was originally isolated from
a brainmetastasis28.We show that the DU145metastatic cell variants
have undergone aMETwhich ismediated via the combined action of
multiple miRNA species.
Results
Development of a new prostate cancer metastasis model. To select
for prostate cancer cells with increased metastatic potential we used
an in vivo cycling strategy23,27 to establish a series of sublines from the
DU145 human prostate cancer cell line28. To establish this model,
2 3 106 DU145 cells were injected orthotopically into the prostate of
nude mice. Tumor growth was monitored by abdominal palpation.
Once the tumor was 0.5–1 cm in diameter (5–12 weeks), the mice
were euthanized and necropsied in a sterile environment. The
sentinel paraaortic lymph nodes were excised, minced and the cells
were placed into culture (schematic in Figure 1A), as described in
Methods. Primary lymph node cultures contained tumor cells and
fibroblasts, but after several passages only tumor cells remained and
were named DU145-LN1. Repeated rounds of lymph node excision
and tumor cell reinjection were performed to establish the DU145-
LN2, DU145-LN3 and DU145-LN4 cell lines. RT-PCR was used to
confirm that the cell cultures were not contaminated with cells of
mouse origin (e.g. fibroblasts) which might affect tumor growth
(Supplementary Figure 1A).
To validate our metastasis model, all of the newly established cell
lines were injected orthotopically into the prostate of mice at the
same time point in a head-to-head comparison. Tumors and lymph
nodes were removed after 5 weeks (Figure 1B). Tissues were fixed in
formalin and embedded in paraffin for immunohistochemical ana-
lysis. Tumor incidence was 100% for all cell lines, while tumor size
increased dramatically in cycled lines (Table 1). Lymph node sections
(3 tissue levels per node, 4–6 mice per group) were analyzed by H&E
staining and human cytokeratin-18 (K18) staining. Lymph node
metastasis was measured as incidence of cytokeratin-18 positive
tumor foci (single K181 cells were excluded). Metastatic
Figure 1 | Selection of DU145 human prostate cancer cells with increased metastatic potential. (A) Schematic of the experimental approach. DU145
prostate cells were injected orthotopically into the prostate. Lymph nodes were removed and cultured, and selected tumor cells subjected to repeated
rounds of orthotopic injection. Illustrations by Kristin Johnson (Vascular Biology Program, Boston Children’s Hospital). (B) Photography of gross
specimens (tumors and sentinel lymph nodes). DU145 parental cells and DU145-LN sublines (DU145-LN4 shown) were reinjected into the prostate and
the prostate and lymph nodes were removed after 5 wks. Scale bar 5 1 cm. (C) Representative H&E staining of lymph nodes from mice bearing
orthotopic parental DU145 tumors (left panel, P) and DU145-LN4 tumors (center and right panels, LN4). Metastatic nodule indicated by arrowhead in
center panel, magnification shown in right panel.
www.nature.com/scientificreports
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Table 1 | In vivo growth of DU145 sublines
Cell Line Injected Tumor Incidence Mean Tumor Volume (mm3 6 SD) Metastatic Incidence*
DU145 5/5 171 6 96 0/4
DU145-LN1 4/4 718 6 336 2/4
DU145-LN2 5/5 1904 6 728 3/4
DU145-LN3 7/7 899 6 628 5/6
DU145-LN4 4/4 488 6 312 3/4
DU145-PR3 3/3 313 6 99 0/3
Cell lines were injected orthotopically into the prostate. Tumors and lymph nodes were removed after 5 weeks.
*Presence of K18-positive metastatic foci in lymph nodes. All available lymph nodes were evaluated.
Figure 2 | Metastatic DU145-LN4 cells show mesenchymal to epithelial-like changes. (A) DU145-LN4 cells display more cell–cell clustering as
seen by phase microscopy (upper panels), and increased E-cadherin immunostaining (lower panels), scale bar 5 50 mm. (B) Microarray analysis shows
increased expression of epithelial markers and decreased mesenchymal markers. Heat map diagram shows unsupervised two-way hierarchical clustering
of genes and cell lines. Color scale shows relative expression level; red is maximum, blue represents minimum expression level. (C) Western blot
confirmed a progressive increase in expression of epithelial markers, and decrease in the mesenchymal marker vimentin, following rounds of metastatic
selection from DU145 to DU145-LN4. One membrane was probed for E-cadherin, EpCAM, and GAPDH. Another was probed for vimentin, claudin 7,
cytokeratin 18, c-catenin, and actin. Images were cropped to save space; original images are shown in Supplemental Figure 5.
www.nature.com/scientificreports
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selection increased the incidence of tumor-cell positive lymph nodes
from 0% in mice bearing parental DU145 tumors, to 75% in mice
bearing DU145-LN4 tumors (Table 1). We were also able to observe
large metastases after H&E staining of the lymph nodes of DU145-
LN4-injected mice (Figure 1C). It is important to note that lymph
nodes from mice bearing DU145 tumors did not have metastases or
obvious K181 foci, although they did have single K181 cells at 5
weeks. It is possible that these single K181 cells would have grown
into larger metastases at later time points.
Metastatic DU145-LN4 cells display a more epithelial-like pheno-
type. The DU145-LN4 metastatic cell line displayed an altered
phenotype, compared to parental DU145 cells, showing increased
cell-cell interactions and cell clusters indicating a more "epithelial-
like" phenotype (Figure 2A, upper panels). E-cadherin immu-
nostaining showed an increased expression level and illustrated the
increased cell-cell interactions in the DU145-LN4 cells (Figure 2A,
lower panels). The intermediate cell lines, DU145-LN1, LN2 and
LN3 also displayed progressively more epithelial-like characteris-
tics (Supplementary Figure 1B). We investigated the gene expres-
sion profile of these cells using an Illumina cDNA expression array.
Using BRB Array Tools software, data were transformed and
normalized as described in Methods. To identify differentially
expressed genes, we applied analysis of variance tools typically
used for time-course analysis. We selected for linear (positive or
negative) gene expression changes, to correspond with the
repeated rounds of in vivo cycles of lymph node metastasis in our
model.We found thatmany of the genes associated with an epithelial
phenotype were dramatically increased. Selection of EMT-related
genes29 showed a pattern of gene expression changes indicating a
progressive mesenchymal to epithelial transition (MET) in our
model. Expression of the epithelial genes, E-cadherin (CDH1),
epithelial cell adhesion molecule (EPCAM), cytokeratin 18
(KRT18), and c-catenin, also known as junctional plakoglobin
(JUP) were significantly increased, and many mesenchymal genes
showed decreased expression, including vimentin (VIM) and
transforming growth factor b-1(TGFB1) (Figure 2B and 2C).
Western blot analysis confirmed these changes at the protein level,
with increased expression of E-cadherin, EpCAM, cytokeratin 18, c-
catenin and claudin 7, and decreased vimentin expression
(Figure 2C). Our cellular model displays discrete and progressive
steps in the process of MET, which correlates with prostate cancer
progression.
As a parallel to our in vivo metastasis selection model, we also
performed repeated rounds of orthotopic prostate injection, estab-
lishing tumor cell lines from the prostate (Figure 3A), as described in
Methods. This scheme created the in vivo prostate-cycled DU145
sublines; DU145-PR1, DU145-PR2 and DU145-PR3. In contrast to
the DU145-LN model, repeated in vivo cycling through the prostate
alone produced no significant change in the metastatic potential of
the cells when reinjected in vivo. This was assessed by cytokeratin 18
staining of excised lymph nodes as described in Methods. No mice
Figure 3 | In vivo prostate-cycled DU145 cells do not display the phenotypic and expression changes observed in the metastatic DU145-LN cell lines.
DU145 cells were injected into the mouse prostate, the prostate excised and grown in culture to create DU145-PR1. This process was repeated to create
DU145-PR2 and DU145-PR3. (A) Photography of DU145-PR3 gross specimens (tumors and sentinel lymph nodes) after 5 weeks following cell line
injection orthotopically into the prostate. Scale bar 5 1 cm (B) Phase contrast microscopy shows similar cell phenotype of DU145 parental and DU145-
PR3 cells in culture. (C)Western blot analysis of DU145-PR3 and parental DU145 cell lysates indicate that expression of E-cadherin, EpCAM, c-catenin,
vimentin and b-catenin were not changed by in vivo cycling through the prostate, in contrast to the expression changes observed in DU145-LN4 cells.
Equal loading shown by actin immunoblots. The same membrane was stripped and reprobed for E-cadherin, EpCAM, c-catenin, vimentin, and actin. A
separate blot was probed for b-catenin and actin. Images were cropped to save space; original images are shown in Supplemental Figure 5. Handwritten
pen marks denote molecular weight markers.
www.nature.com/scientificreports
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bearing DU145-PR3 tumors were positive for metastatic foci
(Table 1). In contrast to the MET-like changes observed in the meta-
static DU145-LN model, no effect was observed in cell morphology
(Figure 3B), and no significant change in expression of E-cadherin,
EpCAM, b-catenin, c-catenin or vimentin was observed in DU145-
PR3 by Western blot (Figure 3C). This suggests that the micro-
environment at the secondary site has a role in either selecting or
differentiating tumor cells that arrive at that site.
Cell plasticity is mediated by increased expression of miR-200c
and miR-141 in DU145 cells. The MET-like program in these cells
suggested a mechanism of coordinated gene expression changes. We
examined the miRNA profile in these cells using miRNA gene chips
and discovered that several miRNAs showed a pattern of progres-
sively increased or decreased expression across themetastatic DU145
cell line model. The most significantly increased miRNAs in the
microarray were those of the miRNA-200 family (miR200a, miR-
200b, miR200c and miR-141). The miR-200 family also includes
miR-429, which also showed some increased expression in the
DU145-LN cell microarray, but did not reach the threshold filter
for further analysis. The most significantly decreased miRNA was
miR-424 (Figure 4). MiR-200c was the most changed miRNA in the
DU145-LN4 microarray data, with 5.5 fold increase in expression
relative to parental DU145, miR-141 was the second most changed
(4.6 fold), followed by miR-200b (3.2 fold) and miR-200a (2.6 fold).
MiR-200 family expression was investigated using real time RT-
PCR. MiR-200a, miR-200b, miR-200c and miR-141 were amplified
from three independent RNA collections of the parental DU145,
DU145-LN2 and DU145-LN4 cells. Data were normalized to the
small housekeeping RNA, SNORD38B. Figure 5A demonstrates that
miR-200a, miR-200b, miR-200c and miR-141 expression were
progressively increased in DU145-LN2 and DU145-LN4 cells, com-
pared to DU145. MiR-200c and miR-141 showed a greater fold
increase in DU145-LN4 relative to DU145 (.7X), compared to
miR-200a or miR-200b (approximately 3X). These expression pat-
terns correlated with the miR-200 family microarray data.
We then investigated whether miR-200 inhibition could reverse
the epithelial phenotype in DU145-LN4 cells. Cells were transfected
with antimiRs to miR-200a, miR-200b, miR-200c and miR-141.
MiR-200c and miR-141 are clustered on chromosome 12, separate
from the chromosome 1 cluster containingmiR-200a, miR-200b and
miR-42930,31. Clusters are often co-regulated and in our model miR-
200c and miR-141 levels were more highly upregulated in DU145-
LN4 cells compared to miRs-200a, and -200b. Consequently,
antimiRs were also combined in these cluster pairs in addition to
combining all four antimiRs. Control cells were transfected with
non-specific antimiR controls at matched concentrations between
100–400 nM (day 0). AntimiR-transfected DU145-LN4 cells were
monitored by phase microscopy, fixed for immunocytochemistry
and whole cell lysates collected at day 3 and day 7. Cells were sub-
jected to a second antimiR transfection on day 7, with samples sub-
sequently collected at day 14. Repeated transfections have been
shown to more effectively induce EMT in previous studies30,32. We
found that antimiR inhibition of the miR-200c and miR-141 cluster
resulted in a more mesenchymal phenotype, with reduced cell-cell
clustering and cell-cell interactions, as observed by phasemicroscopy
and immunocytochemistry for E-cadherin expression at day 14
(Figure 5B and Supplementary Figure 2). AntimiRs targeting miR-
200c or miR-141 were capable of inducing morphologic EMT-like
changes to a similar extent when used individually or combined
(Figure 5B and Supplementary Figure 2). At the protein level,
antimiRs to miR-200c and miR-141 reduced E-cadherin and
EpCAM expression by Western blot analysis. MiR-200c treatment
caused the most significant induction of vimentin expression (alone
or in combination with othermiR-200 family members) (Figure 5C).
Many of the expression changes in EMT markers were more pro-
nounced after repeated transfection and extended treatment to 14
days. For example, by 14 days, antimiR-141 increased vimentin levels
and antimiR to miR-200a inhibited E-cadherin and EpCAM protein
expression (Figure 5D). AntimiR to miR-200b showed no significant
effect on morphology, E-cadherin immunocytochemical staining or
protein marker expression in DU145-LN4 cells. The seed sequences
for functional targets are more similar between miR-200a and miR-
141, than for miR-200c, miR-200b and miR-429. This suggests that
epithelial-mesenchymal plasticity is activated via different mechan-
isms or potentially through shared targets between the two func-
tional clusters30,31. As expected, treatment of DU145-LN4 cells with
antimiR-200c and antimiR-141 caused upregulation of the transcrip-
tion factors, ZEB1 and ZEB2, known mediators of EMT30–34, paired
with reduced E-cadherin (CDH1) expression at the RNA level
(Figure 5E).
MET is mediated via loss of miR-424 in DU145-LN4. We disco-
vered a strong inverse correlation of miR-424 expression with the
epithelial phenotype in DU145 cells. MiR-424 was the most
significantly downregulated miRNA in our microarray analysis
(Figure 4), and the level progressively decreased in the DU145-LN
cell series as the cells became more epithelial. In microarray data
DU145-LN1 showed 1.6 fold, DU145-LN2, 2.1 fold, and DU145-
LN4 2.4 fold down-regulation of miR-424 expression, relative to
parental DU145 cells (Figure 4). We confirmed this change using
real time RT-PCR for miR-424 using RNA prepared from three
individual cell cultures. Expression was normalized to the small
housekeeping RNA, SNORD38B (Figure 6A). In real time RT-
PCR, DU145-LN1 showed only 66% miR-424 expression, LN2
55%, LN3 26% and LN4 25% miR-424 expression, relative to
parental DU145 cells (100%).
Figure 4 | Heat map profile of miRNA expression in the DU145-LN cell
line model. RNA collected from DU145, DU145-LN1, DU145-LN2 and
DU145-LN4 was analyzed using a miRCURY LNA array (Exiqon).
Hierarchical clustering and heat map representation of miRNAs and cell
lines. Global color scale shows maximum (red) and minimum (blue)
miRNA expression level.
www.nature.com/scientificreports
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Figure 5 | The miR-200 family regulates EMT in metastatic DU145-LN4 cells. (A) Real time RT-PCR confirmed increased expression of the miR-200
familymembers; miR-200a, b, c andmiR-141 inDU145-LN2 andDU145-LN4 cells, relative toDU145 cells.Mean1/2 SEMof triplicates. (B) Treatment
of DU145-LN4 cells with a combination of antimiRs to the miR-200a 1 miR-200b (left center panel) or miR-200c 1 miR-141 (right center panel)
reduced cell clustering and cell-cell interactions, as observed by phase-contrast microscopy (upper panels, scale bar 5 100 mm), and E-cadherin
immunostaining (lower panels, scale bar 5 25 mm) at 14 days. Cells were transfected at day 0 and day 7. (C) Western blot at 7 days (following day 0
transfection) and (D) 14 days (following day 0 and day 7 transfection) showed reduced expression of E-cadherin and EpCAM, and increased vimentin
expression following treatment of DU145-LN4 cells with antimiRs 200c 1 141. To account for increased antimiR concentration when treated in
combination, controls were treated with 200 nM (2X) and 400 nM (4X) non-specific antimiR. Actin shown as protein loading control. The same
membrane was stripped and reprobed for each subsequent marker in C or D. Images were cropped to save space; original images are shown in
Supplemental Figure 5. (E) Real time RT-PCR amplification of ZEB1, ZEB2 and CDH1 in DU145LN4 cells treated with antimiR-200c 1 141 (grey bars),
relative to antimiR control (black bars). Data normalized to GAPDH, mean 1/2 SD.
www.nature.com/scientificreports
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Figure 6 | MiRNA-424 regulates the epithelial phenotype. (A) Progressive downregulation of miR-424 expression in the DU145-LN cell series was
measured by real time RT- PCR. (B) DU145-LN4 cells were transfected with two different control premiRs (left and right panels) or premiR-424 (center
panel). PremiR-424 induced EMT-like changes, as observed by reduced cell-cell interactions in phase-contrast microscopy, and decreased E-cadherin and
EpCAM levels in immunostaining. (C) Western blot analysis of DU145-LN4 cells treated with premiR controls, premiR-424 or mock transfected,
collected at 6 and 21 days shows premiR-424 inhibited E-cadherin and EpCAM expression and increased vimentin levels. Actin shown as loading control.
(D) Stable overexpression of miR-424 in DU145-LN4 cells resulted in loss of cell-cell contacts as shown by phase contrast microscopy (scale bar 100 mm).
DU145-LN4 vector control (v3), and two miR-424-overexpressing DU145-LN4 clones (424-2 and 424-8) shown. Upper right panel shows reduced E-
Cadherin, EpCAMand c-catenin and increased vimentin levels byWestern blot. Bar chart of real time PCR data confirmed upregulation ofmiR-424 level
in stable cell lines after normalizing to housekeeping small RNA, SNORD38B. (E) Transient transfection of premiR-424 in epithelialMCF-7 breast cancer
cells resulted in increased cell scattering, relative to two individual control premiRNAs, as shown by phase contrast microscopy (scale bar 50 mm).
Western blot showed decreased E-Cadherin and EpCAM expression in premiR-424-treated cells. b-actin shown as loading control. Each membrane was
stripped and reprobed for each subsequent marker in (C), (D), and (E). Images were cropped to save space; original images are shown in Supplemental
Figure 5.
www.nature.com/scientificreports
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Figure 7 | miR-424 and miR-200c/141 act independently and additively to affect cell plasticity. DU145-LN4 cells were treated with control pre-miR
combined with control antimiR, premiR-424 combined with antimiR control, antimiR-200c/141 combined with premiR control, or antimiR-200c/141
combined with premiR-424. (A) Whole cell lysates were collected at 7 and 14 days. Immunoblots showed reduced E-cadherin and EpCAM expression,
and increased vimentin levels in premiR-424 or antimiR-200c/141 treated cells. Combining these treatments produced additive inhibition of epithelial
markers. The same membrane was stripped and reprobed for each subsequent marker. Images were cropped to save space; original images are shown in
Supplemental Figure 5. (B) In parallel with cell lysate collection, treated cells were examined using phase contrast microscopy and E-cadherin
immunocytochemistry. Cell scattering was more distinct after premiR-424 treatment at 7 days, compared to antimiR-141/200c. At 14 days we observed
additive effects of miR-424 expression and miR-141/200c inhibition, with greater cell scatter and loss of E-cadherin staining.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 3151 | DOI: 10.1038/srep03151 8
To determine whether loss of miR-424 expression was involved in
the phenotypic MET observed in the DU145 metastasis model, we
transfected DU145-LN4 with premiR-424. MiR-424 precursor over-
expression induced cell scattering, as observed by phase contrast
microscopy and immunocytochemistry (Figure 6B), inhibited
expression of the epithelial markers E-cadherin and EpCAM, and
increased expression of the mesenchymal marker, vimentin, as seen
by Western blot analysis (Figure 6C). MiR-424 overexpression
induced similar effects on these EMTmarkers after a single transfec-
tion and protein collection at 6 days, as was seen with second (d7)
and third (d14) re-transfections, with lysate collection at d21,
respectively (Figure 6C).
MiR-424 was then stably overexpressed in DU145-LN4 cells using
a precursor miRNA expression construct (pEZX-miR-424). Stable
clones were selected using puromycin, monitored by fluorescence
microscopy for GFP, and real time RT-PCR was used to confirm
miR-424 overexpression. MiR-424-overexpressing cells showed EMT-
like changes in phenotype, with increased cell scattering, loss of E-
cadherin expression and gain of vimentin expression (Figure 6D).
We observed the same phenotype and expression changes in
DU145-LN4 cells when miR-424 was stably overexpressed using
an alternative construct, pCMV-miR-424 (Supplementary Figure
3B). Similarly, EpCAM levels decreased and vimentin increased
when miR-424 was overexpressed in DU145-LN2 cells (Supple-
mentary Figure 3C–D). To determine whether miR-424 inhibition
could induce a reciprocal MET, we transfected antimiR-424 into
parental DU145 cells. Inhibition of miR-424 expression increased
cell-cell contacts, induced expression of E-cadherin and decreased
expression of vimentin, relative to controls (Supplementary Figure
4A–B). Finally, in addition to effects in the DU145 prostate cancer
model, transfection of precursor miR-424 induced similar EMT-like
changes in other epithelial cell types, including MCF-7 breast cancer
cells (Figure 6E).
Additive effects of miR200c/141 cluster inhibition and miR-424
overexpression on cell plasticity. Our data establish a new role for
miR-424 in tumor cell plasticity. The miR-200 family has been es-
tablished asmaster regulators of EMT30–32. However, even against the
background of high miR-200 expression, overexpression of miR-424
was capable of inducing EMT.
We sought to determine whether manipulation of the miR-424
and miR-200 pathways could act synergistically to regulate tumor
cell EMT. In our model, the epithelial phenotype was represented
by high miR-200 and low miR-424 levels. We transfected epithe-
lial DU145-LN4 cells with anti-miR200c/141 and premiR-424,
alone or in combination. By Western blot analysis, both miR-
424 overexpression and miR-200 inhibition reduced E-cadherin
and EpCAM expression and increased vimentin levels, indicating
an EMT (Figure 7A). Inhibition of miR-200c and miR-141 had a
more dramatic effect on EpCAM and vimentin level, compared to
premiR-424 expression. These markers are known to be targets of
the miR-200 family; EpCAM has been reported to be a target of
miR-200c35, while vimentin is induced by ZEB36. The EMT marker
expression changes were supported by phase microscopy and
immunocytochemical staining for E-cadherin (Figure 7B), which
indicated that at 7 days cell scattering was induced more effec-
tively by miR-424 overexpression, compared to miR-200 inhibi-
tion. By combining miR-200c/141 inhibition and miR-424 over-
expression, a greater reduction in epithelial marker expression was
observed in DU145-LN4 cells after both 7 and 14 days, compared
to either treatment alone (Figure 7A and B). However, vimentin
was more effectively induced by miR-200c/141 inhibition alone,
compared to miR-200c/141 inhibition combined with miR-424
overexpression. Our data suggest that miR-200c/141 and miR-
424 influence cell plasticity through additive, rather than syn-
ergistic effects.
Discussion
We have created a new spontaneous model of prostate cancer meta-
stasis, and show that a progressive mesenchymal to epithelial trans-
ition (MET) occurred as the cells became more metastatic. The role
of phenotypic plasticity along an epithelial to mesenchymal axis in
cancer progression and metastasis has been widely studied and
debated in recent years3–5,7. Compelling evidence is now mounting
for the importance of an epithelioid phenotype for effective coloniza-
tion within secondary tumor sites10–14. Our data builds upon that
evidence and shows in vivo selection for MET within a tumor cell
population. Our selection criterion was metastasis, without any bias
toward phenotype, and we expanded cells that had already success-
fully reached and survived in the lymph node microenvironment.
This indicates spontaneous cell plasticity in response to physical and
microenvironment signals. MET occurred in the intrinsically chaotic
gene expression of a tumor cell population, and was not driven by
ectopic overexpression or inhibition of specific EMT-related tran-
scription factors or miRNAs.
It is quite possible that the EMT/MET status of the cell impacts
lymphatic and vascular metastasis differently. In fact, lymphatic
capillaries contain open gaps and little to no basement membrane
or pericyte coverage, while blood capillaries are surrounded by base-
ment membrane and pericytes37. Lymphatic metastasis can use col-
lective cell migration which may better tolerate a more epithelial
phenotype, whereas vascular invasion can be aided by the amoeboid
motility associated with a more mesenchymal phenotype38–40.
Circulating miR-141 and 200b correlate with positive lymph node
status and metastasis in prostate cancer41,42. Importantly, micro-
metastases must survive and grow at the secondary site to become
clinically relevant, and our data supports the importance of an epi-
thelial phenotype in this process.
Due to the background of aberrant gene expression in any tumor
cell, the process of tumor EMT is reported to involve many different
gene changes dependent on the tumor type. Many genes have been
established as epithelial or mesenchymal markers or EMT media-
tors2,29,43, but within different systems the expression levels of these
are variable and likely driven by different profiles of important reg-
ulators such as TGF-b1, transcription factors (including SNAI1,
SNAI2, ZEB1, ZEB2 and TWIST1) or miRNAs. E-cadherin loss
and vimentin gain are central to the process of EMT, but other key
genes in embryonic EMT, e.g. N-cadherin, may be less relevant in
some tumor cells. Tumor cells frequently adopt an intermediate
phenotype characterized by expression of both epithelial and
mesenchymal markers. The nature of this plasticity is being studied
intensively by many laboratories.
DU145 human prostate cancer cells have been described as hav-
ing an ‘‘undefined’’ phenotype because their molecular profile
shows expression of both epithelial and mesenchymal expression
markers30. As such, they provide an excellent starting point for
studies on epithelial-mesenchymal plasticity. They show population
heterogeneity; epithelial subpopulations have been selected by FACS
sorting for E-cadherin44 and mesenchymal subpopulations selected
by cell invasion45. Within our DU145-LN model of MET we observe
a more comprehensive shift toward epithelial markers (Figure 2),
compared to mesenchymal markers. We show that the global shift
in EMT/MET related genes is driven by both the miR-200 family
and miR-424 in these cells and that they act antagonistically on
phenotype. Our data shows multiple changes in epithelial markers
upon manipulation of these miRNAs, including E-cadherin, Ep-
CAM, cytokeratin 18, b- and c-catenins. The miR-200 family is well
established as a modulator of EMT. MiR-200 family members bind
the transcriptional repressors ZEB1 and ZEB2, resulting in in-
creased E-cadherin levels30–34, and DU145 express relatively low
miR-200b and miR-200c when compared to other cells in the
NCI-60 panel of cell lines12. In our system miR-200c inhibition
caused the most dramatic EMT, among all miR-200 family
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members, and upregulation of both ZEB1 and ZEB2 was seen after
miR-200c inhibition.
MiR-424 has not previously been shown to mediate tumor plas-
ticity. In our model miR-424 expression could induce epithelial to
mesenchymal phenotype changes as effectively as miR-200c. In fact,
we consistently observedmore dramatic changes in morphology and
EMT-related marker expression at an earlier timepoint with miR-
424 overexpression, compared to miR-200c inhibition. The additive
effects on EMT from combining miR-424 overexpression with miR-
200 inhibition suggest these miRNAs are acting on epithelial to
mesenchymal plasticity via complementary mechanisms. Certainly,
there are no predicted seed sequences for miR-424 in the 3’UTRs of
either ZEB1 or ZEB2.
Relatively little is known about the effects of miR-424. In cancer
studies, low miR-424 correlates with lymph node metastasis and
poor patient outcomes in cervical cancer46. In this system the tumor
suppressive effects of miR-424 are mediated via protein checkpoint
kinase 1 (CHEK1), which did not significantly change in our DU145
model. Another recent report showed inhibition of osteosarcoma cell
migration and invasion by miR-424 expression47. In non-tumor tis-
sue, miR-424 has been implicated in maintaining the physiology of
vasculature48–51, and blood cell differentiation52.
MiR-424 is a member of the miR-16 family which includes
miRNA-15/16/195/424/497. These miRNAs share a ‘seed region’
in the 5’UTRwhichmay result in some overlappingmiRNA targets53.
MiR-15a and miR-16 decrease in advanced prostate cancers, with
knockdown promoting tumorigenesis54, and miR-16 delivery
reduced growth of prostate tumors in bone55. These effects were
mediated via cell cycle-related genes BCL2, CCND1, WNT3A54.
Indeed, in our model, CCND1 mRNA increased with metastatic
potential, but DU145-LN4 cells did not show increased proliferation
rates, compared to DU145 (J.Banyard, unpublished data). However,
it is possible that other overlapping miRNA-16 family targets are
involved in the increased tumorigenesis and metastasis that we
observe in the DU145-LN metastasis model.
We identified a number of potential miR-424 targets in our sys-
tem, using MIR@NT@N network analysis56, which combined
miRNA and gene expression data from the DU145-LN model,
together with analysis of gene expression data from PremiR-424
overexpression in DU145-LN4 cells. While we validated most of
these as targets of miR-424 (e.g. DSC2, F11R, MYB and VAMP8),
siRNA knockdown (individually or in combination) was unable to
affect cellular plasticity and recapitulate the effects of miR-424
expression in DU145-LN4 cells (J. Banyard, unpublished results).
Thus, the mechanism through which miR-424 induces cell plasticity
remains under investigation. Our data has identified miR-424 as a
novel pivotal actor which is necessary and sufficient to induce EMT
and is a new counterbalance of the miR-200 family. Deciphering the
different miRNA-424 target networks may be useful for tumor
metastasis.
Together, our results provide support for the emerging hypothesis
that acquisition of an epithelial phenotype promotes expansion of
metastatic colonies. We further provide a novel model that allows
interrogation of this process in prostate cancermetastasis. Finally, we
implicate miR-424 as a novel regulator of tumor cell plasticity.
Methods
Cell culture and transfection. DU145 human prostate cancer cells were maintained
in high glucose DMEM with 10% fetal bovine serum (FBS), 1% glutamine, penicillin
and streptomycin (GPS), and 1% sodium pyruvate (Invitrogen, Carlsbad, CA). MCF-
7 cells were grown in Eagle’sMinimumEssential Mediumwith 10% FBS, 1%GPS and
0.01 mg/ml human recombinant insulin (Sigma-Aldrich, St. Louis, MO). Cell lines
were obtained from ATCC (Manassas, VA).
For transfection, 63 105 DU145-LN4 or 23 105 DU145 cells were seeded in 6 well
plates in serum-containing media. Cells were transfected while in suspension using
25 nMAmbion Pre-miRmiRNA precursor (Life Technologies) diluted in OptiMEM
media (Invitrogen), and complexed using siLentFect transfection reagent (Biorad,
Hercules, CA). Cells were allowed to attach overnight and media replaced the next
day. For repeated and extendedmiRNA treatments, cells were passaged as needed and
trypsinized and transfected in suspension at specific time points. Cells were trans-
fected at d0, d7 and d14. Whole cell lysates were collected from d0 transfected cells at
d3, d6 and d7, collected from d0 1 d7 transfected cells at d14, and d0 1 d7 1 d14
transfected cells at d21. Pre-miR miRNAs included negative controls #1 and #2 and
Pre-miR-424. Control cells were mock transfected in parallel. Loss of function studies
were performed by transfection of the miRIDIAN microRNA hairpin inhibitors
(Dharmacon/Thermo Scientific), anti-hsa-miR-424, anti-hsa-miR-200a, anti-hsa-
miR-200b, anti-hsa-miR-200c and anti-hsa-miR-141 or antimiR control at 100 nM,
under the same experimental conditions.
Stable DU145-LN4 and DU145-LN2 cells expressing miR-424 were established by
infection with pEZX-MR03 lentiviral vector containing the miRNA precursor clone
of hsa-miR-424 (pEZX-miR-424) or scrambled miRNA control clone (GeneCopoeia,
Rockville, MD). Expressing clones were selected with puromycin. Additional stable
miR-424 overexpressing DU145-LN4 cells were created by FuGENE 6 (Promega,
Madison, WI) transfection with pCMV-MIR424 plasmid (Origene Technologies,
Rockville, MD). Vector controls were transfected with empty pCMV vector, and
stable cells were selected using neomycin.
Phase contrast and fluorescent microscopy images were captured using a Nikon
Eclipse TE200 microscope with an RT SPOT camera and SPOT Advanced v4.0.9.
software (Diagnostic Instruments, Inc., Sterling Heights, MI).
Western blot analysis.Whole cell lysates were collected inmodified RIPAbuffer with
EGTA and EDTA (Boston Bioproducts, Ashland, MA) with protease inhibitor
cocktail (P8340, Sigma-Aldrich). Protein concentration was measured using a BCA
protein assay kit (Pierce/Thermo Scientific). 20 mg or 50 mg reduced protein in
Laemmli sample buffer was resolved using SDS-PAGE and transferred to
Immobilon-P 0.45 mm PVDF membrane (EMD Millipore, Billerica, MA).
Membranes were blocked with 5% non-fat dry milk in PBS, incubated with primary
antibody, followed by the appropriate secondary IgG antibody; anti-mouse, rabbit or
goat-HRP (GE Healthcare). Membranes were washed thoroughly between steps
using PBS containing 0.05% Tween, and developed using ECL Plus Western blotting
detection kit (GE Healthcare). Primary antibodies used: E-cadherin and b-catenin
(BD Biosciences), EpCAM (C-10) and claudin-7 (Santa Cruz Biotechnology, Dallas,
TX), vimentin (V9) (Dako, Carpinteria, CA), GAPDH (6C5) (Abcam), b-actin
(Sigma), c-catenin (Cell Signaling Technology), and cytokeratin-18 (Epitomics,
Burlingame, CA). Blots were stripped using ReBlot Plus Strong Antibody stripping
solution (EMD Millipore) before reprobing.
RNA and miRNA purification and expression analysis. Cells were washed with ice
cold PBS and RNA or miRNA purified. RNA was purified using RNeasy mini RNA
purification kit (Qiagen). RNA samples were hybridized to an Illumina Ref. 8 bead
chip (Illumina, San Diego, CA) at the IDDRC Cell & Molecular Genetics Core
Facility, Genetics Division at Boston Children’s Hospital. For analysis of miR-424
targets, RNA was collected following 24 hr treatment of DU145-LN4 cells with Pre-
miR controls #1 and #2, Pre-miR-424 (Ambion) and syn-hsa-miR-424 (Qiagen).
RNA was hybridized to U133 Plus 2.0 gene chips (Affymetrix, Santa Clara, CA). For
miRNA analysis, total RNA containingmiRNAwas purified using anmiRNeasymini
kit (Qiagen). MiRNA labeling, hybridization, scanning and expression profiling was
performed using miRCURY LNA microarray service (Exiqon).
PCR. Total RNA for PCR was reverse transcribed using iScript cDNA synthesis kit
(BioRad). cDNA fromDU145, DU145-LN and B16-F10 cell lines was amplified using
mouse and human GAPDH primers with iQ SYBR Green Supermix (Biorad) using a
DNA Engine Thermal Cycler (Biorad) machine. DNAwas separated on a 2% agarose
gel containing ethidium bromide. B16-F10mousemelanoma cell cDNAwas included
as a positive control for mouse DNA. Real time PCR was performed using a DNA
Engine Opticon 2 machine (MJ Research) and analyzed using Opticon 3.1 software
(Biorad Laboratories). cDNAwas amplified using primers tomouse GAPDH, human
GAPDH, CDH1 and ZEB1 (Real Time Primers, Elkins Park, PA), and ZEB2, FWD
59CAAGAGGCGCAAACAAGC and REV 59GGTTGGCAATACCGTCATCC57.
miRNA was copied using the miRCURY LNA Universal cDNA synthesis kit
(Exiqon) followed by PCR using iQ SYBR Green Supermix (Biorad) with miRNA
LNA PCR primer sets to hsa-miR-200a, has-miR-200b, hsa-miR-200c, hsa-miR-141,
hsa-miR-424 and the reference gene primer sets; U6 snRNA (hsa, mmu, rno) and
SNORD38B (hsa) (Exiqon). Each sample was amplified in duplicate or triplicate.
Animal studies and development of metastatic DU145-LN model. Orthotopic
prostate injection of 8 week male nu/nu mice with DU145 cells and sublines was
performed. All animal experiments were approved by the IACUC committee of
Boston Children’s Hospital. Briefly, mice were anesthetized and an abdominal
incision was made to expose the prostate. 2 3 106 cells were injected into the prostate
using 40 ml cells in Hanks Balanced Salt Solution in each of two ventral lobes,
delivered using a mini-injector. Tumor growth was monitored by palpation. After
5–12 weeks (5 weeks for direct comparison experiment), mice were sacrificed and
necropsied to remove tumors and sentinel paraaortic lymph nodes for culture, or
formalin fixation, paraffin embedding and tissue analysis. For culture, tissues were
washed with PBS, minced through a 100 mM BD Falcon cell strainer (BD
Biosciences), washed twice by centrifugation in PBS, and plated on tissue culture
dishes in complete media. After attachment overnight, cells were washed thoroughly
with PBS, media replaced and cells grown to create DU145-PR1 (from prostate) or
DU145-LN1 (from lymph node). After expansion in culture, in vivo orthotopic
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prostate injection was repeated for additional rounds of selection. Note: while making
the cycledmodel cell lines, lymph nodes were cultured; but in the direct head-to-head
comparison of all lines in vivo, lymph nodes were embedded and evaluated for
metastases.
Immunocytochemistry and immunohistochemistry. For immunocytochemistry,
cells were plated on cover slips, and treated in parallel with cells for Western blot
analysis. Cells were fixed with 4% paraformaldehyde in PBS at experimental time
points. Cells were blocked with 2% BSA in TBS, permeabilized in TBS containing
0.01% Triton X100, and incubated with E-cadherin primary antibody (BD-
Biosciences) and anti-mouse Alexa Fluor-488 (Invitrogen). Nuclei were stained using
DAPI and coverslips mounted with Vectashield mounting media (Vector Labs). No
significant staining was seen with secondary antibody controls.
For tissue immunohistochemistry, paraffin embedded lymph nodes were rehy-
drated and stained with hematoxylin and eosin, or cytokeratin-18. Heat induced
epitope retrieval was performed with citrate buffer (pH 6). Tissue was blocked using
normal serum and incubated with cytokeratin 18 antibody (Epitomics) and bioti-
nylated anti-rabbit (Vector Laboratories, Burlingame, CA) followed by Vectastain
Elite (avidin-HRP; Vector), and developedwith diaminobenzidine (DAB,Vector). To
detect human epithelial cell metastases, sentinel lymph node sections were stained
with cytokeratin 18 antibody and counterstained with hematoxylin. Sections were
examined by microscopy and cytokeratin 18 positive cells grouped in small foci were
scored as metastases. Three different tissue levels from each of two lymph nodes
(when available) were examined per mouse.
Statistical analysis. miRNA microarray data was analyzed by miRCURY LNA
microarray service (Exiqon). Data was normalized using the non-parametric
regression method, LOESS. Unsupervised two-way clustering of miRNAs and
samples was performed on log2 (Hy3/Hy5) ratios (with each sample versus the
common reference pool) to produce a heat map. Illumina Ref. 8 gene expression data
from the DU145-LN metastasis model was processed using average normalization
with background subtraction. Normalized data was analyzed using BRB-ArrayTools
(Biometrics Research Branch, National Cancer Institute) and analysis of variance
across a time course of DU145,DU145-LN1,DU145-LN2,DU145-LN4 groups
was performed. Heat map expression data was displayed using Gene-E software
developed by Joshua Gould (http://www.broadinstitute.org/cancer/software/GENE-
E). Hierarchical clustering using one minus Pearson’s correlation was applied to
samples and genes/miRNAs. Global or relative map colors were applied using the
minimum and maximum values in the data. Network analysis to identify miRNA
targets using gene and miRNA expression data was performed using MIR@NT@N56.
1. Gupta, G. P. & Massague, J. Cancer metastasis: building a framework. Cell 127,
679–695 (2006).
2. Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition.
J Clin Invest 119, 1420–1428 (2009).
3. Tarin, D., Thompson, E. W. & Newgreen, D. F. The fallacy of epithelial
mesenchymal transition in neoplasia.Cancer Res 65, 5996–6000; discussion 6000-
5991; (2005).
4. Thompson, E. W., Newgreen, D. F. & Tarin, D. Carcinoma invasion and
metastasis: a role for epithelial-mesenchymal transition? Cancer Res 65,
5991–5995 discussion 5995 (2005).
5. Garber, K. Epithelial-to-mesenchymal transition is important to metastasis, but
questions remain. J Natl Cancer Inst 100, 232–233 239 (2008).
6. Ledford, H. Cancer theory faces doubts. Nature 472, 273 (2011).
7. Chui, M. H. Insights into cancer metastasis from a clinicopathologic perspective:
Epithelial-Mesenchymal Transition is not a necessary step. Int J Cancer 132,
1487–1495 (2013).
8. Weinberg, R. A. Leaving home early: reexamination of the canonical models of
tumor progression. Cancer Cell 14, 283–284 (2008).
9. Brabletz, T. To differentiate or not--routes towardsmetastasis.Nat Rev Cancer 12,
425–436 (2012).
10. Chaffer, C. L. et al. Mesenchymal-to-epithelial transition facilitates bladder cancer
metastasis: role of fibroblast growth factor receptor-2. Cancer Res 66,
11271–11278 (2006).
11. Chao, Y. L., Shepard, C. R. & Wells, A. Breast carcinoma cells re-express E-
cadherin duringmesenchymal to epithelial reverting transition.Mol Cancer 9, 179
(2010).
12. Korpal, M. et al. Direct targeting of Sec23a by miR-200s influences cancer cell
secretome and promotes metastatic colonization.NatMed 17, 1101–1108 (2011).
13. Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S. & Yang, J. Spatiotemporal
regulation of epithelial-mesenchymal transition is essential for squamous cell
carcinoma metastasis. Cancer Cell 22, 725–736 (2012).
14. Ocana, O. H. et al. Metastatic colonization requires the repression of the
epithelial-mesenchymal transition inducer Prrx1.Cancer Cell 22, 709–724 (2012).
15. Tse, J. C. & Kalluri, R. Mechanisms of metastasis: epithelial-to-mesenchymal
transition and contribution of tumor microenvironment. J Cell Biochem 101,
816–829 (2007).
16. Zhang, J. & Ma, L. MicroRNA control of epithelial-mesenchymal transition and
metastasis. Cancer Metastasis Rev 31, 653–662 (2012).
17. Bullock, M. D., Sayan, A. E., Packham, G. K. & Mirnezami, A. H. MicroRNAs:
critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to
epithelial transition (MET) in cancer progression. Biol Cell 104, 3–12 (2012).
18. Siegel, R. et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin 62, 220–241 (2012).
19. Cheng, L. et al. Lymphovascular invasion is an independent prognostic factor in
prostatic adenocarcinoma. J Urol 174, 2181–2185 (2005).
20. Karakiewicz, P. I. & Hutterer, G. C. Predictive models and prostate cancer. Nat
Clin Pract Urol 5, 82–92 (2008).
21. Sleeman, J. P. & Thiele, W. Tumor metastasis and the lymphatic vasculature. Int J
Cancer 125, 2747–2756 (2009).
22. Wilt, T. J. et al. Radical prostatectomy versus observation for localized prostate
cancer. N Engl J Med 367, 203–213 (2012).
23. Stephenson, R. A. et al. Metastatic model for human prostate cancer using
orthotopic implantation in nude mice. J Natl Cancer Inst 84, 951–957 (1992).
24. Fidler, I. J. The organ microenvironment and cancer metastasis. Differentiation
70, 498–505 (2002).
25.Hanahan,D.&Weinberg, R. A.Hallmarks of cancer: the next generation.Cell 144,
646–674 (2011).
26. Sottnik, J. L., Zhang, J., Macoska, J. A. & Keller, E. T. The PCa Tumor
Microenvironment. Cancer Microenviron 4, 283–297 (2011).
27. Pettaway, C. A. et al. Selection of highly metastatic variants of different human
prostatic carcinomas using orthotopic implantation in nudemice.Clin Cancer Res
2, 1627–1636 (1996).
28. Stone, K. R., Mickey, D. D.,Wunderli, H., Mickey, G. H. & Paulson, D. F. Isolation
of a human prostate carcinoma cell line (DU 145). Int J Cancer 21, 274–281
(1978).
29. Taube, J. H. et al. Core epithelial-to-mesenchymal transition interactome gene-
expression signature is associated with claudin-low and metaplastic breast cancer
subtypes. Proc Natl Acad Sci U S A 107, 15449–15454 (2010).
30. Park, S. M., Gaur, A. B., Lengyel, E. & Peter, M. E. The miR-200 family determines
the epithelial phenotype of cancer cells by targeting the E-cadherin repressors
ZEB1 and ZEB2. Genes Dev 22, 894–907 (2008).
31. Korpal, M., Lee, E. S., Hu, G. & Kang, Y. The miR-200 family inhibits epithelial-
mesenchymal transition and cancer cell migration by direct targeting of E-
cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283,
14910–14914 (2008).
32. Gregory, P. A. et al. The miR-200 family and miR-205 regulate epithelial to
mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10, 593–601
(2008).
33. Hurteau, G. J., Carlson, J. A., Spivack, S. D. & Brock, G. J. Overexpression of the
microRNA hsa-miR-200c leads to reduced expression of transcription factor 8
and increased expression of E-cadherin. Cancer Res 67, 7972–7976 (2007).
34. Burk, U. et al. A reciprocal repression between ZEB1 andmembers of themiR-200
family promotes EMT and invasion in cancer cells. EMBO Rep 9, 582–589 (2008).
35. Cochrane, D. R., Spoelstra, N. S., Howe, E. N., Nordeen, S. K. & Richer, J. K.
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-
targeting chemotherapeutic agents. Mol Cancer Ther 8, 1055–1066 (2009).
36. Bindels, S. et al. Regulation of vimentin by SIP1 in human epithelial breast tumor
cells. Oncogene 25, 4975–4985 (2006).
37. Zwaans, B. M. & Bielenberg, D. R. Potential therapeutic strategies for lymphatic
metastasis. Microvasc Res 74, 145–158 (2007).
38. Friedl, P. & Gilmour, D. Collective cell migration in morphogenesis, regeneration
and cancer. Nat Rev Mol Cell Biol 10, 445–457 (2009).
39. Giampieri, S. et al. Localized and reversible TGFbeta signalling switches breast
cancer cells from cohesive to single cell motility. Nat Cell Biol 11, 1287–1296
(2009).
40. Hager, M. H. et al. DIAPH3 governs the cellular transition to the amoeboid
tumour phenotype. EMBO Mol Med 4, 743–760 (2012).
41. Brase, J. C. et al. Circulating miRNAs are correlated with tumor progression in
prostate cancer. Int J Cancer 128, 608–616 (2011).
42. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for
cancer detection. Proc Natl Acad Sci U S A 105, 10513–10518 (2008).
43. Zeisberg, M. & Neilson, E. G. Biomarkers for epithelial-mesenchymal transitions.
J Clin Invest 119, 1429–1437 (2009).
44. Putzke, A. P. et al. Metastatic progression of prostate cancer and e-cadherin
regulation by zeb1 and SRC family kinases. Am J Pathol 179, 400–410 (2011).
45. Chunthapong, J. et al. Dual roles of E-cadherin in prostate cancer invasion. J Cell
Biochem 91, 649–661 (2004).
46. Xu, J. et al. Suppressed miR-424 expression via upregulation of target gene Chk1
contributes to the progression of cervical cancer. Oncogene 32, 976–987 (2012).
47. Long, X. H. et al. Tumor suppressive microRNA-424 inhibits osteosarcoma cell
migration and invasion via targeting fatty acid synthase. Exp Ther Med 5,
1048–1052 (2013).
48. Ghosh, G. et al. Hypoxia-induced microRNA-424 expression in human
endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis. J Clin
Invest 120, 4141–4154 (2010).
49. Kim, J. et al. An endothelial apelin-FGF linkmediated bymiR-424 andmiR-503 is
disrupted in pulmonary arterial hypertension. Nat Med 19, 74–82 (2013).
50. Nakashima, T. et al. Down-regulation of mir-424 contributes to the abnormal
angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to
therapy. PLoS One 5, e14334 (2010).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 3151 | DOI: 10.1038/srep03151 11
51. Chamorro-Jorganes, A. et al. MicroRNA-16 and microRNA-424 regulate cell-
autonomous angiogenic functions in endothelial cells via targeting vascular
endothelial growth factor receptor-2 and fibroblast growth factor receptor-1.
Arterioscler Thromb Vasc Biol 31, 2595–2606 (2011).
52. Rosa, A. et al. The interplay between the master transcription factor PU.1 and
miR-424 regulates human monocyte/macrophage differentiation. Proc Natl Acad
Sci U S A 104, 19849–19854 (2007).
53. Forrest, A. R. et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-
503, promotes monocytic differentiation through combinatorial regulation.
Leukemia 24, 460–466 (2010).
54. Bonci, D. et al. The miR-15a-miR-16-1 cluster controls prostate cancer by
targeting multiple oncogenic activities. Nat Med 14, 1271–1277 (2008).
55. Takeshita, F. et al. Systemic delivery of synthetic microRNA-16 inhibits the
growth of metastatic prostate tumors via downregulation of multiple cell-cycle
genes. Mol Ther 18, 181–187 (2010).
56. Le Bechec, A. et al. MIR@NT@N: a framework integrating transcription factors,
microRNAs and their targets to identify sub-network motifs in a meta-regulation
network model. BMC Bioinformatics 12, 67 (2011).
57. Fassina, A. et al. Epithelial-mesenchymal transition in malignant mesothelioma.
Mod Pathol 25, 86–99 (2012).
Acknowledgments
Research reported in this publication was supported by grants from the Prostate Cancer
Foundation (BRZ), and by the National Institutes of Health under award numbers, NIH
R01 CA37393 (BRZ), NIH R21 CA155728 (DRB) and NIH K01 CA118732 (DRB). This
content is solely the responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health. We thank Courtney Barrows, Milind
Chalishazar and Andrea Henricks for technical assistance, Melissa Anderson for
administrative assistance, and Kristin Johnson for graphical preparation of figures. We
acknowledge Ricardo Sanchez, HTL (Ricasan Histology Consultants) for tissue sections.
Author contributions
J.B. conceived the experiments, performed all the experiments, analyzed and interpreted
data, and wrote the manuscript. I.C. contributed to the experimental design and edited the
manuscript, A.M.W. performed experiments in Fig. 2, 5, 6 and 7. G.V. and A.L.B. analyzed
and interpreted data and edited the manuscript. D.R.B. conceived the experiments,
performed the experiments in Fig. 1, Fig. 3 and Table 1, analyzed and interpreted data,
contributed to the experimental design and edited the manuscript. B.R.Z. conceived the
experiments and edited the manuscript.
Additional information
Accession Codes: The data discussed in this publication have been deposited in NCBI’s
Gene Expression Omnibus and are accessible through GEO SuperSeries record number
GSE51756.
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Banyard, J. et al. Regulation of epithelial plasticity by miR-424 and
miR-200 in a new prostate cancer metastasis model. Sci. Rep. 3, 3151; DOI:10.1038/
srep03151 (2013).
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 Unported license. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 3151 | DOI: 10.1038/srep03151 12
